Molecular and Cellular Biochemistry

, Volume 234, Issue 1, pp 225–228 | Cite as

Endogenous regulation of the acute inflammatory response

  • Peter A. Ward
  • Alex B. Lentsch
Article

Abstract

The acute inflammatory response has been triggered in rat lungs by deposition of IgG immune complexes. The inflammatory reaction triggered is highly tissue damaging and requires activation of NF-κB with ensuing generation of chemokines and cytokines. Endogenous generation of IL-10 and IL-13 as well as secretory leukocyte protease inhibitor (SLPI), significantly regulates this inflammatory response. IL-10 and IL-13 attenuate NF-κB activation by interfering with breakdown of IκBα, while SLPI likewise suppresses NF-κB activation, but by interfering with breakdown of IκBβ. Antibody induced blockade of IL-10, IL-13 or SLPI enhances NF-κB activation in lung and exacerbates the lung inflammatory response and injury. These data indicate that endogenous IL-10, IL-13 and SLPI are important regulators of the inflammatory response by reducing gene activation with resultant generation of peptide mediators/cytokines and chemokines.

NF-κB inflammation lung injury neutrophils 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Johnson KJ, Ward PA: Acute immunologic pulmonary alveolitis. J Clin Invest 54: 349–357, 1974PubMedGoogle Scholar
  2. 2.
    Warren JS, Yabroff KR, Remick DG, Kunkel SL, Chensue SW, Kunkel RG, Johnson KJ, Ward PA: Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest 84: 1873–1882, 1989PubMedGoogle Scholar
  3. 3.
    Warren JS: Intrapulmonary interleukin 1 mediates acute immune complex alveolitis in the rat. Biochem Biophys Res Commun 175: 604–610, 1991PubMedGoogle Scholar
  4. 4.
    Shanley TP, Schmal H, Warner RL, Schmid E, Friedl HP, Ward PA: Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J Immunol 158: 3439–3448, 1997PubMedGoogle Scholar
  5. 5.
    Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA: Role of macrophage inflammatory protein-1α (MIP-1α) in acute lung injury in rats. J Immunol 154: 4793–4802, 1995PubMedGoogle Scholar
  6. 6.
    Bless NM, Huber-Lang M, Guo RF, Warner RL, Schmal H, Czermak BJ, Shanley TP, Crouch LD, Lentsch AB, Sarma V, Mulligan MS, Freidl HP, Ward PA: Role of CC chemokines (MIP-1β, MCP-1, RANTES) in acute lung injury in rats. J Immunol 164: 2650–2659, 2000PubMedGoogle Scholar
  7. 7.
    Ghosh S, May MJ, Kopp EB: NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225–260, 1998PubMedGoogle Scholar
  8. 8.
    Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853–6866, 1999PubMedGoogle Scholar
  9. 9.
    Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J Clin Invest 100: 2443–2448, 1997PubMedGoogle Scholar
  10. 10.
    Lentsch AB, Czermak BJ, Bless NM, Ward PA. NF-κB activation during IgG immune complex-induced lung injury. Requirements for TNF-α and IL-1β but not complement. Am J Pathol 152: 1327–1336, 1998PubMedGoogle Scholar
  11. 11.
    Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA: Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J Immunol 154: 3454–3460, 1995PubMedGoogle Scholar
  12. 12.
    Lentsch AB, Czermak BJ, Jordan JA, Ward PA: Regulation of acute lung inflammatory injury by endogenous IL-13. J Immunol 162: 1071–1076, 1999PubMedGoogle Scholar
  13. 13.
    Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr: Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274: 31868–31874, 1999PubMedGoogle Scholar
  14. 14.
    Manna SK, Aggarwal BB: IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. J Immunol 161: 2863–2872, 1998PubMedGoogle Scholar
  15. 15.
    Schill WB, Wallner O, Schiessler H, Fritz H: Immunofluorescent localization of the acid-stable proteinase inhibitor (antileukoprotease) of human cervical mucus. Experientia 34: 509–510, 1978PubMedGoogle Scholar
  16. 16.
    Lee CH, Igarashi Y, Hohman RJ, Kaulbach H, White MV, Kaliner MA: Distribution of secretory leukoprotease inhibitor in the human nasal airway. Am Rev Respir Dis 147: 710–716, 1993PubMedGoogle Scholar
  17. 17.
    Fryksmark U, Jannert M, Ohlsson K, Tegner H, Wihl JA: Secretory leukocyte protease inhibitor in normal, allergic and virus induced nasal secretions. Rhinology 27: 97–103, 1989PubMedGoogle Scholar
  18. 18.
    Fryksmark U, Ohlsson K, Polling A, Tegner H: Distribution of antileukoprotease in upper respiratory mucosa. Ann Otol Rhinol Laryngol 91: 268–271, 1982PubMedGoogle Scholar
  19. 19.
    Moriyama A, Shimoya K, Kawamoto A, Hashimoto K, Ogata I, Kunishige I, Ohashi K, Azuma C, Saji F, Murata Y: Secretory leukocyte protease inhibitor (SLP) concentrations in seminal plasma: SLPI restores sperm motility reduced by elastase. Mol Hum Reprod 4: 946–950, 1998PubMedGoogle Scholar
  20. 20.
    Ohlsson K, Bjartell A, Lilja H: Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl 16: 64–74, 1995PubMedGoogle Scholar
  21. 21.
    Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 83: 6692–6696, 1986PubMedGoogle Scholar
  22. 22.
    Eisenberg SP, Hale KK, Heimdal P, Thompson RC. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 265: 7976–7981, 1990PubMedGoogle Scholar
  23. 23.
    Mulligan MS, Desrochers PE, Chinnaiyan AM, Gibbs DF, Varani J, Johnson KJ, Weiss SJ. In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci USA 90: 11523–11527, 1993PubMedGoogle Scholar
  24. 24.
    Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, Ward PA. Inhibition of NF-κB activation and augmentation of IκBα by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 154: 239–247, 1999PubMedGoogle Scholar
  25. 25.
    Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, Sarma V, Gibbs DF, Tefera W, McConnell PC, Mueller WT, Johnson KJ, Ward PA: Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol 162: 3653–3662, 1999PubMedGoogle Scholar
  26. 26.
    Mulligan MS, Lentsch AB, Huber-Lang M, Guo RF, Sarma V, Wright CD, Ulich TR, Ward PA: Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol 156: 1033–1039, 2000PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Peter A. Ward
    • 1
  • Alex B. Lentsch
    • 1
  1. 1.Department of PathologyUniversity of MichiganAnn ArborUSA

Personalised recommendations